The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

US FDA grants priority review status to Bayer’s sevabertinib to treat patients with HER2-mutant non-small cell lung cancer: Berlin Friday, May 30, 2025, 16:00 Hrs [IST] Bayer an ...

Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.

A phase 2 trial found that adding bevacizumab to alectinib significantly delayed disease progression, protected against brain ...

Among the 43 evaluable patients treated with sevabertinib, the confirmed objective response rate was 72.1%.

After Merck paid a hefty sum to co-develop and co-commercialize HER3-DXd, the drug has suffered notable setbacks in ...

Breathing in wildfire pollution may make it harder for people with lung cancer to survive, according to a new study from UC ...

David P. Carbone, MD, PhD, discusses the outcomes of the phase 3 CheckMate 9LA trial in non–small cell lung cancer based on ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

New targeted therapies allow for the treatment of a disease that is already the fifth leading cause of fatal tumors globally ...